Indivi has entered into a partnership with Biogen. Through this collaboration with the US biotechnology group, Indivi plans to develop digital biomarkers for Parkinson’s disease, as the Basel-based medtech firm writes in a press release. To this end, Indivi intends to merge Biogen’s Konectom biomarker platform with its own digital biomarker platform for multiple sclerosis known as dreaMS.
“Through this multi-year strategic collaboration with Biogen, we aim to expand the reach of our unique technology to a new critical disease area where innovation is crucially needed and that may cross-fertilize with the progress of our scientific efforts in multiple sclerosis”, comments Guilhem Dupont, CEO of Indivi, before adding: “This collaboration is a testament to the hard work and dedication of our entire team over the past five years in developing transformative digital measurements to support research in neuroscience”.
The first step will involve Konectom being used in the Phase 2b LUMA study focused on an active ingredient for the treatment of early-stage Parkinson’s disease developed in conjunction with Denali Therapeutics. In addition, Biogen and Indivi are interested in jointly developing new digital endpoints for Parkinson’s. It is hoped that the merger of Konectom and dreaMS will lead to the development of digital measurement technology covering all key areas of neurology.
